Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment